Developer docs
API playgroundTry for free, no card

Search company profiles

Isogenica

Full company profile

uuid0008cku

Namestring
Isogenica
Legal namestring
Isogenica Limited
Websiteurl
isogenica.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Isogenica Limited is a Cambridge, UK-based biotechnology company founded in 2000 that specializes in custom VHH (variable domain of heavy chain) single-domain antibody discovery and engineering. The company operates a fee-for-service Contract Research Organization (CRO) model, delivering synthetic, animal-free VHH antibody candidates to biotech and pharmaceutical partners. Its core technology stack combines proprietary in vitro CIS Display™ (validated in peer-reviewed literature since 2004) with three synthetic VHH libraries — LlamdA® (~10^13 diversity), huLlamdA™ (~10^12), and VHHantage® (~10^10) — claimed to be the world's largest synthetic VHH libraries. Supporting modules include ISOXTEND® half-life extension, COLIBRA® codon-precision library construction, and C-terminal cysteine conjugation for ADCs.

The commercial offering spans VHH discovery services, affinity maturation, humanization, peptide discovery, and applications across bi-specifics, multi-specifics, CAR-T, ADCs, intrabodies, and radiopharmaceuticals. Discovery contracts follow a standard structure: a 4–6 week panning/screening phase delivering up to 100 antibody sequences, a 12-month evaluation window for up to five selected antibodies, and an exclusive license to commercialize. The model is explicitly fee-for-service with no milestones, royalties, or success fees on the standard engagement, with optional rolling FTE arrangements.

The customer base spans large pharma (AstraZeneca, Pfizer, Johnson & Johnson, Takeda, BioNTech), clinical-stage biotech (Arvinas, Harpoon, Aro, Cerberus Therapeutics, Wellmarker Bio), and government/academic institutions (Frederick National Laboratory, Oncode Institute). Isogenica has delivered over 100 programs and reports 3 clinical-stage assets and 9 partnered preclinical assets in its pipeline. The company has built a Discovery Network integrating Charles River Laboratories, Axxam, and Cube Biotech to extend its offering from hit identification through GLP preclinical development. Revenue is not publicly disclosed and no major institutional funding round beyond a 2012 Innovate UK grant is recorded in the source data.

Short descriptiontext

Isogenica is a Cambridge, UK-based CRO specializing in custom VHH single-domain antibody discovery using proprietary synthetic libraries and CIS Display™ technology, serving biotech and pharma clients on a fee-for-service basis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLittle Chesterford, United Kingdom
HQ citystring
Little Chesterford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, VHH antibody engineering, synthetic antibody libraries, peptide discovery services, therapeutic antibody development
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Antibody Discovery CRO Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fee-for-Service Discovery Contracts
TypeProfessional Services
Description

Custom VHH antibody discovery services delivered under fee-for-service contracts. Following screening phase (4-6 weeks), up to 100 deliverable antibody sequences are shared for evaluation. Up to five Selected Antibodies may be identified for further development. Commercial model is straightforward: Fee-for-Service with no milestones, royalties, or success fees.

isogenica.com
2Rolling FTE Model
TypeProfessional Services
Description

Flexible staffing model where clients can engage Isogenica scientists on a time-and-materials basis for ongoing discovery programs.

isogenica.com
3Licensing Revenue
TypeLicensing Royalties
Description

Exclusive license to five Selected Antibodies grants full rights to develop, optimize, patent, publish, and commercialize each candidate. Antibodies are digitally withdrawn from library and not shared or licensed to any other party.

isogenica.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Panning & Screening Phase
ModelOtherBilling cadenceMulti-year contract
Notes

Initial screening phase typically 4-6 weeks, delivering up to 100 antibody sequences for client evaluation

isogenica.com
2Characterisation & Evaluation
ModelOtherBilling cadenceMulti-year contract
Notes

Up to five Selected Antibodies may be identified for further development. 12-month evaluation window begins upon delivery of final project report.

isogenica.com
3Final Deliverables & Licensing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Exclusive license to five Selected Antibodies with full rights to develop, optimize, patent, publish, and commercialize each candidate.

isogenica.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1LlamdA®
Description

Proprietary synthetic VHH library with over 10^13 diversity, based on llama-derived frameworks

isogenica.com
+5 more records
Core offering1 text field

Isogenica provides custom VHH (Variable Domain of Heavy Chain) single-domain antibody discovery services powered by the world's largest proprietary synthetic libraries (LlamdA®, huLlamdA™, VHHantage®) and CIS Display™ in vitro selection technology. The service spans antibody discovery campaigns, affinity maturation, humanisation, half-life extension (ISOXTEND®), ADC conjugation handles, and licensing of selected antibodies for therapeutic development, complemented by custom peptide discovery on the same CIS Display platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100+ programmes delivered with multiple leads progressed to clinic
+3 more records
Product overview1 text field

Isogenica (The VHH Company™) is a UK-based antibody discovery company offering a platform of synthetic VHH (variable domain of heavy chain) antibody technologies. The core offering centers on three proprietary synthetic VHH libraries—LlamdA® (~10^13), huLlamdA™ (~10^12), and VHHantage® (~10^10)—combined with CIS Display™ and phage display technologies for antibody and peptide discovery. Discovery services are augmented by engineering modules including VHH Affinity Maturation and Humanisation, half-life extension via ISOXTEND®, and C-terminal cysteine conjugation for ADC development. Applications span bi-specific and multi-specific antibodies, CAR-T cell therapy, antibody-drug conjugates, intrabodies, and radiopharmaceuticals. The company operates a Discovery Network integrating specialist CROs (Charles River, Axxam, Cube Biotech) for seamless hit-to-IND workflows.

Product and service8 records
1VHH Antibody Discovery Services
CategoryVHH Antibody Discovery
Description

Custom fee-for-service VHH single-domain antibody discovery for biotech and pharmaceutical companies, including panning and screening (4-6 weeks), delivery of up to 100 antibody sequences, identification of up to five Selected Antibodies, and optional 12-month evaluation window before exclusive licensing.

2Synthetic VHH Libraries (LlamdA®, huLlamdA™, VHHantage®)
CategorySynthetic Antibody Libraries
Description

Three proprietary synthetic VHH antibody libraries offering >10^13 (LlamdA®), ~10^12 (huLlamdA™ pre-humanized), and ~10^10 (VHHantage®) sequence diversity, used to deliver IP-clean, high-affinity single-domain antibodies without animal immunization.

3CIS Display™ Technology
CategoryDisplay Technology Platform
Description

DNA-based in vitro display technology enabling selection of peptides and VHHs from extremely large libraries, licensed and used as a scalable discovery engine for biotech and pharma customers (e.g., Arvinas for PROTAC® platform expansion; Wellmarker Bio; AstraZeneca for peptide discovery against targets such as phospholamban).

4Phage Display Screening Service
CategoryDisplay Technology Platform
Description

Phage display screening service complementing CIS Display for antibody and peptide discovery campaigns across diverse target classes.

5ISOXTEND® Half-Life Extension Technology
CategoryAntibody Engineering Platform
Description

Half-life extension technology using cross-species serum albumin binders, validated in vivo with up to 26-hour half-life in mouse (16–19 days in humans), applicable to mono-, bi- and multi-specific antibodies.

6VHH Affinity Maturation and Engineering
CategoryAntibody Engineering Service
Description

Affinity maturation and engineering service to optimize VHH leads for potency, developability, and integration into multi-specifics, ADCs, and targeted lipid nanoparticles.

7VHH Humanisation Service
CategoryAntibody Engineering Service
Description

VHH humanization service using rational humanisation or CDR grafting, supported by pre-humanized huLlamdA™ and VHHantage® libraries that reduce immunogenicity risk and downstream engineering effort.

8Custom Peptide Discovery Service
CategoryPeptide Discovery Service
Description

Custom peptide discovery using CIS Display technology with 8× off-the-shelf libraries (linear or constrained formats, 8–16 variable positions, beta turns available), used for research collaborations with pharma partners including AstraZeneca.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Antibody discovery agreement to support development of targeted immune-modulating therapies using single-domain antibodies. VHHs identified through the program integrate into Cerberus's KappaLink™ platform for engaging Fc receptor-positive effector cells.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Collaboration to accelerate peptide and VHH discovery, uniting Isogenica's synthetic discovery platforms with Charles River's drug discovery and development expertise. Together they offer integrated route from hit identification to candidate selection and GLP preclinical development, streamlining the path to clinic for biotech companies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-16
Description

Strategic collaboration to accelerate GPCR therapeutics by combining Cube Biotech's advanced GPCR stabilization technology (NativeMP™) with Isogenica's synthetic VHH libraries and CIS Display technology. Provides seamless solution for GPCR-targeted therapeutics including GLP-1R and other complex transmembrane proteins.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-26
Description

Partnership bringing together functional bioassay capabilities with unique VHH antibody discovery solutions. Combines Isogenica's VHH expertise with Axxam's high-throughput screening and functional assay capabilities for ADC and other functional antibody discovery programs.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-03-28
Description

Multi-project contract developing molecules for clinical laboratory assays to measure biomarkers correlated with molecular effectiveness of cancer immuno-oncology agents. Relationship has expanded with two additional projects added to the contractual relationship.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-05-30
Description

MoU for collaboration in research and development of antibody-based cancer immunotherapy, Protein-Protein Interaction (PPI) Inhibitors, biomarkers and peptide libraries. Joint funding including UK or other government grants to create portfolio of preclinical programs.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-01-18
Description

Technology license agreement where Arvinas leverages Isogenica's CIS Display technology to support advancing and expanding its PROTAC® platform for targeted protein degradation therapeutics in oncology and neuroscience.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement using Isogenica's VHH single-domain antibody libraries for discovery, development and commercialisation of therapeutic products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration using CIS display to identify and characterize novel Centyrins™ against target antigens provided by Aro.

10Oncode Institute (University Medical Center Utrecht)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership for development of anti-LRP6 VHH inhibitors targeting Wnt signaling pathway in cancer therapy. Research led to Nature Communications publication demonstrating potent Wnt pathway inhibition and tumor growth reduction.

isogenica.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Innovate UK-supported collaboration demonstrating effective VHH expression from Baker's yeast (Saccharomyces cerevisiae) systems. Project achieved 10-20-fold increase in fully active VHH product using Phenotypeca's QTL Technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading yeast-display-based antibody discovery CRO serving pharma and biotech with custom monoclonal antibody programs. Comparable as a fee-for-service antibody discovery partner with proprietary display technology, though Adimab focuses on conventional scFv/Fab rather than VHH.

TypeDirect peer
Description

Synthetic biology company offering synthetic antibody libraries (including VHH and single-domain formats) via Twist Biopharma. Direct competitor in the synthetic VHH library space, leveraging DNA synthesis at scale as the source of library diversity rather than CIS Display.

TypeBroad incumbent
Description

Pioneer in VHH/nanobody therapeutics, now part of Sanofi following 2018 acquisition. Ablynx's caplacizumab (Cablivi) was the first approved VHH, validating the modality Isogenica serves. Comparable as a VHH platform but operates at vastly larger scale inside Sanofi.

TypeBroad incumbent
Description

Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services at massive scale. Competes with Isogenica for outsourced antibody discovery work, particularly from pharma clients, but with end-to-end capabilities extending to GMP manufacturing.

TypeDirect peer
Description

Global VHH/nanobody platform company that originated from the VHH space Isogenica serves. Both develop single-domain antibody therapeutics using llama-derived frameworks, but Argenx operates its own commercial pipeline (efgartigimod/Vyvgart) rather than pure CRO services.

TypeEmerging player
Description

Italian functional screening and assay development CRO partnering with Isogenica. Comparable as a specialist CRO serving drug discovery, particularly for ion channels and GPCRs, with overlapping customer base in pharma/biotech.

TypeEmerging player
Description

Specialist in membrane protein stabilization and nanodisc technology, partnered with Isogenica for GPCR antibody discovery. Comparable niche CRO with proprietary enabling technology (NativeMP) targeting the same difficult antigen class (GPCRs, transporters).

TypeBroad incumbent
Description

Public antibody discovery platform combining single-cell sequencing, display technologies, and AI. Provides CRO-style antibody discovery to pharma, similar to Isogenica, but with a much broader technology stack (mAbs, multi-specifics) and public-company scale.

TypeDirect peer
Description

Cambridge, UK-based developer of T cell-engaging VHH (Humabody) therapeutics. Closest pure-play peer in geography and modality, focused on VHH discovery and internal pipeline development for immuno-oncology, with overlapping target space in oncology and T-cell engagers.

TypeBroad incumbent
Description

Global CRO with end-to-end drug discovery and development services including antibody discovery, preclinical, and manufacturing. Strategic partner of Isogenica and a competitor in adjacent discovery and IND-enabling services at much larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Isogenica

Antibody Discovery CRO Servicesisogenica.com

Isogenica is a Cambridge, UK-based CRO specializing in custom VHH single-domain antibody discovery using proprietary synthetic libraries and CIS Display™ technology, serving biotech and pharma clients on a fee-for-service basis.

What Isogenica does

Isogenica Limited is a Cambridge, UK-based biotechnology company founded in 2000 that specializes in custom VHH (variable domain of heavy chain) single-domain antibody discovery and engineering. The company operates a fee-for-service Contract Research Organization (CRO) model, delivering synthetic, animal-free VHH antibody candidates to biotech and pharmaceutical partners. Its core technology stack combines proprietary in vitro CIS Display™ (validated in peer-reviewed literature since 2004) with three synthetic VHH libraries — LlamdA® (~10^13 diversity), huLlamdA™ (~10^12), and VHHantage® (~10^10) — claimed to be the world's largest synthetic VHH libraries. Supporting modules include ISOXTEND® half-life extension, COLIBRA® codon-precision library construction, and C-terminal cysteine conjugation for ADCs.

The commercial offering spans VHH discovery services, affinity maturation, humanization, peptide discovery, and applications across bi-specifics, multi-specifics, CAR-T, ADCs, intrabodies, and radiopharmaceuticals. Discovery contracts follow a standard structure: a 4–6 week panning/screening phase delivering up to 100 antibody sequences, a 12-month evaluation window for up to five selected antibodies, and an exclusive license to commercialize. The model is explicitly fee-for-service with no milestones, royalties, or success fees on the standard engagement, with optional rolling FTE arrangements.

The customer base spans large pharma (AstraZeneca, Pfizer, Johnson & Johnson, Takeda, BioNTech), clinical-stage biotech (Arvinas, Harpoon, Aro, Cerberus Therapeutics, Wellmarker Bio), and government/academic institutions (Frederick National Laboratory, Oncode Institute). Isogenica has delivered over 100 programs and reports 3 clinical-stage assets and 9 partnered preclinical assets in its pipeline. The company has built a Discovery Network integrating Charles River Laboratories, Axxam, and Cube Biotech to extend its offering from hit identification through GLP preclinical development. Revenue is not publicly disclosed and no major institutional funding round beyond a 2012 Innovate UK grant is recorded in the source data.

Isogenica firmographics

Firmographics
Name
Isogenica
Legal name
Isogenica Limited
Website
https://isogenica.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Isogenica is a Cambridge, UK-based CRO specializing in custom VHH single-domain antibody discovery using proprietary synthetic libraries and CIS Display™ technology, serving biotech and pharma clients on a fee-for-service basis.
Ownership category
akta.pro rank

Isogenica industry classification

Industry
Product category
Antibody Discovery CRO Services
NAICS
Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery services
  • VHH antibody engineering
  • Synthetic antibody libraries
  • Peptide discovery services
  • Therapeutic antibody development

Where Isogenica is headquartered

Location

Headquarters

HQ city
Little Chesterford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Isogenica business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Fee-for-Service Discovery Contracts: Custom VHH antibody discovery services delivered under fee-for-service contracts. Following screening phase (4-6 weeks), up to 100 deliverable antibody sequences are shared for evaluation. Up to five Selected Antibodies may be identified for further development. Commercial model is straightforward: Fee-for-Service with no milestones, royalties, or success fees.
  2. Rolling FTE Model: Flexible staffing model where clients can engage Isogenica scientists on a time-and-materials basis for ongoing discovery programs.
  3. Licensing Revenue: Exclusive license to five Selected Antibodies grants full rights to develop, optimize, patent, publish, and commercialize each candidate. Antibodies are digitally withdrawn from library and not shared or licensed to any other party.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPanning & Screening Phase
OtherMulti-year contractCharacterisation & Evaluation
One time/ perpetual licenseMulti-year contractFinal Deliverables & Licensing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Isogenica product offering

Product offering

Core offering

Isogenica provides custom VHH (Variable Domain of Heavy Chain) single-domain antibody discovery services powered by the world's largest proprietary synthetic libraries (LlamdA®, huLlamdA™, VHHantage®) and CIS Display™ in vitro selection technology. The service spans antibody discovery campaigns, affinity maturation, humanisation, half-life extension (ISOXTEND®), ADC conjugation handles, and licensing of selected antibodies for therapeutic development, complemented by custom peptide discovery on the same CIS Display platform.

Product overview

Isogenica (The VHH Company™) is a UK-based antibody discovery company offering a platform of synthetic VHH (variable domain of heavy chain) antibody technologies. The core offering centers on three proprietary synthetic VHH libraries—LlamdA® (~10^13), huLlamdA™ (~10^12), and VHHantage® (~10^10)—combined with CIS Display™ and phage display technologies for antibody and peptide discovery. Discovery services are augmented by engineering modules including VHH Affinity Maturation and Humanisation, half-life extension via ISOXTEND®, and C-terminal cysteine conjugation for ADC development. Applications span bi-specific and multi-specific antibodies, CAR-T cell therapy, antibody-drug conjugates, intrabodies, and radiopharmaceuticals. The company operates a Discovery Network integrating specialist CROs (Charles River, Axxam, Cube Biotech) for seamless hit-to-IND workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • LlamdA®: Proprietary synthetic VHH library with over 10^13 diversity, based on llama-derived frameworks
  • huLlamdA™
  • VHHantage®
  • CIS Display™
  • ISOXTEND®
  • COLIBRA®

Products and services

  • VHH Antibody Discovery Services Custom fee-for-service VHH single-domain antibody discovery for biotech and pharmaceutical companies, including panning and screening (4-6 weeks), delivery of up to 100 antibody sequences, identification of up to five Selected Antibodies, and optional 12-month evaluation window before exclusive licensing.
  • Synthetic VHH Libraries (LlamdA®, huLlamdA™, VHHantage®) Three proprietary synthetic VHH antibody libraries offering >10^13 (LlamdA®), ~10^12 (huLlamdA™ pre-humanized), and ~10^10 (VHHantage®) sequence diversity, used to deliver IP-clean, high-affinity single-domain antibodies without animal immunization.
  • CIS Display™ Technology DNA-based in vitro display technology enabling selection of peptides and VHHs from extremely large libraries, licensed and used as a scalable discovery engine for biotech and pharma customers (e.g., Arvinas for PROTAC® platform expansion; Wellmarker Bio; AstraZeneca for peptide discovery against targets such as phospholamban).
  • Phage Display Screening Service Phage display screening service complementing CIS Display for antibody and peptide discovery campaigns across diverse target classes.
  • ISOXTEND® Half-Life Extension Technology Half-life extension technology using cross-species serum albumin binders, validated in vivo with up to 26-hour half-life in mouse (16–19 days in humans), applicable to mono-, bi- and multi-specific antibodies.
  • VHH Affinity Maturation and Engineering Affinity maturation and engineering service to optimize VHH leads for potency, developability, and integration into multi-specifics, ADCs, and targeted lipid nanoparticles.
  • VHH Humanisation Service VHH humanization service using rational humanisation or CDR grafting, supported by pre-humanized huLlamdA™ and VHHantage® libraries that reduce immunogenicity risk and downstream engineering effort.
  • Custom Peptide Discovery Service Custom peptide discovery using CIS Display technology with 8× off-the-shelf libraries (linear or constrained formats, 8–16 variable positions, beta turns available), used for research collaborations with pharma partners including AstraZeneca.

Quantifiable outcome

  • 100+ programmes delivered with multiple leads progressed to clinic
  • +3 more outcomes

Companies that use Isogenica

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Isogenica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature7 records

Isogenica partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major, core and minor.

  • Cerberus TherapeuticsmajorStrategic or Co-development Partner · 17 June 2025Antibody discovery agreement to support development of targeted immune-modulating therapies using single-domain antibodies. VHHs identified through the program integrate into Cerberus's KappaLink™ platform for engaging Fc receptor-positive effector cells.
  • Charles River LaboratoriescoreStrategic or Co-development Partner · 4 June 2025Collaboration to accelerate peptide and VHH discovery, uniting Isogenica's synthetic discovery platforms with Charles River's drug discovery and development expertise. Together they offer integrated route from hit identification to candidate selection and GLP preclinical development, streamlining the path to clinic for biotech companies.
  • Cube BiotechcoreTechnology or Integration · 16 January 2025Strategic collaboration to accelerate GPCR therapeutics by combining Cube Biotech's advanced GPCR stabilization technology (NativeMP™) with Isogenica's synthetic VHH libraries and CIS Display technology. Provides seamless solution for GPCR-targeted therapeutics including GLP-1R and other complex transmembrane proteins.
  • Axxam S.p.A.coreStrategic or Co-development Partner · 26 September 2024Partnership bringing together functional bioassay capabilities with unique VHH antibody discovery solutions. Combines Isogenica's VHH expertise with Axxam's high-throughput screening and functional assay capabilities for ADC and other functional antibody discovery programs.
  • Frederick National Laboratory for Cancer Research (FNLCR)majorStrategic or Co-development Partner · 28 March 2023Multi-project contract developing molecules for clinical laboratory assays to measure biomarkers correlated with molecular effectiveness of cancer immuno-oncology agents. Relationship has expanded with two additional projects added to the contractual relationship.
  • Wellmarker Bio (WMBIO)majorStrategic or Co-development Partner · 30 May 2022MoU for collaboration in research and development of antibody-based cancer immunotherapy, Protein-Protein Interaction (PPI) Inhibitors, biomarkers and peptide libraries. Joint funding including UK or other government grants to create portfolio of preclinical programs.
  • ArvinasmajorOEM/ Whitelabel/ Licensing Partner · 18 January 2019Technology license agreement where Arvinas leverages Isogenica's CIS Display technology to support advancing and expanding its PROTAC® platform for targeted protein degradation therapeutics in oncology and neuroscience.
  • TakedamajorOEM/ Whitelabel/ Licensing PartnerLicensing agreement using Isogenica's VHH single-domain antibody libraries for discovery, development and commercialisation of therapeutic products.
  • ArominorStrategic or Co-development PartnerCollaboration using CIS display to identify and characterize novel Centyrins™ against target antigens provided by Aro.
  • Oncode Institute (University Medical Center Utrecht)majorStrategic or Co-development PartnerPartnership for development of anti-LRP6 VHH inhibitors targeting Wnt signaling pathway in cancer therapy. Research led to Nature Communications publication demonstrating potent Wnt pathway inhibition and tumor growth reduction.
  • PhenotypecaminorStrategic or Co-development PartnerInnovate UK-supported collaboration demonstrating effective VHH expression from Baker's yeast (Saccharomyces cerevisiae) systems. Project achieved 10-20-fold increase in fully active VHH product using Phenotypeca's QTL Technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Isogenica competitors and assessment

Company assessment

Direct peers

  • Adimab: Leading yeast-display-based antibody discovery CRO serving pharma and biotech with custom monoclonal antibody programs. Comparable as a fee-for-service antibody discovery partner with proprietary display technology, though Adimab focuses on conventional scFv/Fab rather than VHH.
  • Twist Bioscience: Synthetic biology company offering synthetic antibody libraries (including VHH and single-domain formats) via Twist Biopharma. Direct competitor in the synthetic VHH library space, leveraging DNA synthesis at scale as the source of library diversity rather than CIS Display.
  • Argenx: Global VHH/nanobody platform company that originated from the VHH space Isogenica serves. Both develop single-domain antibody therapeutics using llama-derived frameworks, but Argenx operates its own commercial pipeline (efgartigimod/Vyvgart) rather than pure CRO services.
  • Crescendo Biologics: Cambridge, UK-based developer of T cell-engaging VHH (Humabody) therapeutics. Closest pure-play peer in geography and modality, focused on VHH discovery and internal pipeline development for immuno-oncology, with overlapping target space in oncology and T-cell engagers.

Broad incumbents

  • Ablynx (Sanofi): Pioneer in VHH/nanobody therapeutics, now part of Sanofi following 2018 acquisition. Ablynx's caplacizumab (Cablivi) was the first approved VHH, validating the modality Isogenica serves. Comparable as a VHH platform but operates at vastly larger scale inside Sanofi.
  • WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services at massive scale. Competes with Isogenica for outsourced antibody discovery work, particularly from pharma clients, but with end-to-end capabilities extending to GMP manufacturing.
  • AbCellera Biologics: Public antibody discovery platform combining single-cell sequencing, display technologies, and AI. Provides CRO-style antibody discovery to pharma, similar to Isogenica, but with a much broader technology stack (mAbs, multi-specifics) and public-company scale.
  • Charles River Laboratories: Global CRO with end-to-end drug discovery and development services including antibody discovery, preclinical, and manufacturing. Strategic partner of Isogenica and a competitor in adjacent discovery and IND-enabling services at much larger scale.

Emerging players

  • Axxam: Italian functional screening and assay development CRO partnering with Isogenica. Comparable as a specialist CRO serving drug discovery, particularly for ion channels and GPCRs, with overlapping customer base in pharma/biotech.
  • Cube Biotech: Specialist in membrane protein stabilization and nanodisc technology, partnered with Isogenica for GPCR antibody discovery. Comparable niche CRO with proprietary enabling technology (NativeMP) targeting the same difficult antigen class (GPCRs, transporters).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Isogenica social profiles

Digital presence

Isogenica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Isogenica leadership team

Management profile

Number of profiles

Profiles6 records

Isogenica funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Isogenica M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isogenica

What does Isogenica do?

Isogenica provides custom VHH (Variable Domain of Heavy Chain) single-domain antibody discovery services powered by the world's largest proprietary synthetic libraries (LlamdA®, huLlamdA™, VHHantage®) and CIS Display™ in vitro selection technology. The service spans antibody discovery campaigns, affinity maturation, humanisation, half-life extension (ISOXTEND®), ADC conjugation handles, and licensing of selected antibodies for therapeutic development, complemented by custom peptide discovery on the same CIS Display platform.

Is Isogenica a public or private company?

Isogenica is a private company. It is classified as unknown and is currently operating.

When was Isogenica founded?

Isogenica was founded in 2001. It employs 11 to 50 people.

Where is Isogenica based?

Isogenica is headquartered in Little Chesterford, United Kingdom, in the Europe region.

How does Isogenica make money?

Three revenue lines are on record. Fee-for-Service Discovery Contracts are the primary driver. The others are rolling FTE Model and licensing Revenue.

Who are Isogenica's main competitors?

Direct peers on record are Adimab, Twist Bioscience, Argenx and Crescendo Biologics. Broad incumbents are Ablynx (Sanofi), WuXi Biologics, AbCellera Biologics and Charles River Laboratories. Emerging players are Axxam and Cube Biotech.

Does Isogenica have an API?

No public API is recorded for Isogenica.

What industry is Isogenica in?

Isogenica's product category is Antibody Discovery CRO Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 5417 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals